ClinicalTrials.gg
CompletedNCT01433692CANABICUpdated Nov 9, 2026

CANABIC : CANnabis and Adolescents, a Brief Intervention (BI) to Reduce Their Consumption

An interventional study of Brief Intervention in Addictions, Adolescents and Primary Health Care, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 15 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Other

How we know · 2 judgments

Updated Nov 9, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
15 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Behavior, Addictive with a site in France — 33 open to participants now, 34 under way, none of them phase 3. Behavior, Addictive · France.

Enrollment
5th of 34
261 · median 88
Started
2012
with 1 other
No phase
33 of 77
13 open now
Registered
6th of 77
by date
Lead sponsor
8 of 77
University Hospital, Clermont-Ferrand

Among the 77 studies in Behavior, Addictive with a site in France, this one is the 5th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2012, is one of 33 with no phase, and was the 6th registered.

Behavior, Addictive

522 studies on the registry are indexed under Behavior, Addictive; 125 are open to participants now.

Browse Behavior, Addictive studies →

Open to participants now

33 of the 77 studies in Behavior, Addictive with a site in France are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 81 Behavior, Addictive studies recruiting now, 45 (56%) set no upper age limit and 34 (42%) stop at 75 or younger; 7 take children under 18; 24 take healthy volunteers.

This study: 15 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Behavior, Addictive with a site in France, or all of them as a file.
02

Study summary

Background: Cannabis is the most prevalent illegal drug used in France, and consequences arising from the step of 'casual consumers'(1-10 joints/month). Side effects of cannabis are now well documented: Trauma (driving after consuming cannabis), respiratory, cardiovascular diseases and psychiatric and social problems. The general practitioner (GP) is the health professional most viewed by adolescents. Brief interventions (BI) for adult alcohol use have been shown to be efficient. Some BI have been designed to inspect adolescents and consumption of cannabis have been piloted, showing their feasibility, but no test has validated them.

Aim : Does a BI conducted by general practitioners reduce consumption of canabis in 15 to 19 years old ?

Method:

Two preliminary qualitative studies (with adolescents and GP), were used to analyze the difficulties of communication around cannabis use. The Scientific Committee has analyzed the results and developed a workshop around BI, adapted to adolescents cannabis users.

CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).

The study will be carried out in 3 french regions : Auvergne, Rhône-Alpes and Languedoc-Roussillon. 150 GPs wil be recruited and randomized in intervention group or control group (ratio 1 :1).

Each GP will inlcude 5 adolescents (i.e. a total of 750 adolescents) - . The number of adolescents needed has been calculate with hypothesis of a significant difference of 30% in consumption of cannabis between adolescents who beneficied of BI (IG) and those who do not experienced BI ( CG) A pilot study has been conducted. Cannabis use by adolescents has decreased. Their perception of cannabis has changed: they are aware of the harmful effects of their consumption. This pilot study has improve many points of the protocol.

Results:

A decrease of 30% of consumption is expected (joints per month). Perception of cannabis by adolescents will be reviewed.

Conclusions:

To validate an IB adaptated to consultation with adolscents cannabis consumer in order to provide a tool for GP in their daily practice.

Read the detailed description

General organisation of the study

  • Recruitment of the GP: 3 months (from December 2011 to March 2012)
  • Training of the intervention group GP during a one-day training, in March 2012, on 3 thematic: relationship between GP and adolescent, cannabis and BI; by an expert team
  • Inclusion period : 10 months (from April 2012 to January 2013). The included patients will be followed for 12 months. There are 3 follow up consultations at 3, 6 and 12 months.
  • First consultation used to the inclusion:

Information to the patient and collection of the patient non opposition (without informing the intervention objectives in the control group).

Evaluation of cannabis consumption, but also tobacco and alcohol consumption. Collection of the perception of cannabis by adolescents, and its impact on health.

Inclusion criteriae : repetead users : 1 to 10 per month; regular users : 11 to 29 per month; daily users : 1 and more per day.

In the IG : achievment of the BI with the adolescent. In each group, making appointment with the patient at 3 months

  • Follow up consultations : At 3, 6 and 12 months. Evaluation of cannabis consumption, but also tobacco and alcohol consumption. Collection of the perception of cannabis by adolescents, and its impact on health.
03

Conditions studied

  • Addictions
  • Adolescents
  • Primary Health Care
  • Brief Intervention

Browse trials for

Keywords

  • Addictions
  • Adolescents
  • Primary Health Care
  • Brief Intervention
04

Who can participate

Ages eligible
15 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents 15 to 25 years Repetead users : 1 to 10 per month; regular users : 11 to 29 per month; daily users : 1 and more per day.

The patient must have given his and signed the form of no objection

Exclusion criteria

Exclusion Criteria:

  • Adolescents with psychiatric illness considered by the attending physician in acute decompensated
  • Intellectual Disability
  • Hard of hearing
  • No French language skills
  • Patient already under treatment for the withdrawal of an addicition to cannabis or other substance
  • Adolescents who participated in the preliminary qualitative study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
261 participants (actual)

Study arms

  • Experimental
    intervention group

    Behavioral: Brief Intervention

  • Other
    control group

    Behavioral: Brief Intervention

Interventions

  • BehavioralBrief Intervention

    CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).

06

What researchers measure

Primary outcomes

  1. the number of joints consumed per month

    Time frame: at 12 months

Secondary outcomes

  1. the number of joints consumed per month

    Time frame: at 3 and at 6 months

07

Study locations

1 site
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 63003, France
08

References and documents

Publications

  • Laporte C, Vaillant-Roussel H, Pereira B, Blanc O, Eschalier B, Kinouani S, Brousse G, Llorca PM, Vorilhon P. Cannabis and Young Users-A Brief Intervention to Reduce Their Consumption (CANABIC): A Cluster Randomized Controlled Trial in Primary Care. Ann Fam Med. 2017 Mar;15(2):131-139. doi: 10.1370/afm.2003. PubMed 28289112 ↗
  • Laporte C, Lambert C, Pereira B, Blanc O, Authier N, Balayssac D, Brousse G, Vorilhon P. Cannabis users: Screen systematically, treat individually. A descriptive study of participants in a randomized trial in primary care. PLoS One. 2019 Dec 2;14(12):e0224867. doi: 10.1371/journal.pone.0224867. eCollection 2019. PubMed 31790425 ↗
  • Laporte C, Vaillant-Roussel H, Pereira B, Blanc O, Tanguy G, Frappe P, Costa D, Gaboreau Y, Badin M, Marty L, Clement G, Dubray C, Falissard B, Llorca PM, Vorilhon P. CANABIC: CANnabis and Adolescents: effect of a Brief Intervention on their Consumption--study protocol for a randomized controlled trial. Trials. 2014 Jan 30;15:40. doi: 10.1186/1745-6215-15-40. PubMed 24479702 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Mar 2014, 24 months.

Of 148 non-industry interventional studies with no phase under Behavior, Addictive, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 42. This study's 24 months is below that.

Counting every sponsor, half of 156 studies reached it within 26 months; a quarter within 10 and three quarters within 42.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2014 → Mar 2015, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2011
First posted
Sep 14, 2011
StartActual
Mar 1, 2012
Primary completionActual
Mar 30, 2014
CompletionActual
Mar 2015was Jul 2014
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 9, 2026
Study completion
Jul 2014→Mar 2015 (actual)
Nov 9, 2026
Enrollment
750 (estimated)→261 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Status unknown→Completed
    Study completion Jul 2014→Mar 2015 (now actual)
    Enrollment 750 (estimated)→261 (actual)
    + 5 other changes: verification date, design details, contact details, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01433692
Responsible party
Sponsor
First posted
Sep 14, 2011
Start date
Mar 1, 2012
Primary completion
Mar 30, 2014
Completion
Mar 2015
Last update
Nov 9, 2026

Study contacts

Catherine LAPORTE, MD
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion